AbbVie Inc. (BVMF:ABBV34)

Market Cap	2.06T +15.5%
Revenue (ttm)	336.87B +8.6%
Net Income	23.28B -1.2%
EPS	13.00 -1.3%
Shares Out	n/a
PE Ratio	88.55
Forward PE	15.28
Dividend	1.54 (2.17%)
Ex-Dividend Date	Jan 15, 2026

Volume	3,208
Average Volume	1,699
Open	70.64
Previous Close	74.08
Day's Range	70.37 - 72.02
52-Week Range	60.00 - 81.36
Beta	0.33
RSI	45.14
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: ABBV34

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD